ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A Randomized Multicenter Phase III Study to Evaluate the Role of All-trans Retinoic Acid
(ATRA) in Combination with Induction Chemotherapy, or Azacitidine and Idarubicin as salvage
therapy and Idarubicin with Cytarabine or Azacitidine as Maintenance Therapy in Older
Patients with Acute Myeloblastic Leukemia (AML).
To compare the outcome of elderly patients with newly-diagnosed AML treated with standard
induction chemotherapy and post-remission therapy, in only patients in CR, with either
azacitidine or cytarabine combined to idarubicin +/- ATRA and salvage therapy with
azacitidine combined to idarubicin +/- ATRA.